m88 casino Assisted Antengene in Entering into a Global Clinical Collaboration with MSD

m88 casino December 27, Antengene Corporatim88 casino Limited (“Antengene”) announced that it had entered a global clinical collaboratim88 casino with MSD to jointly cm88 casinoduct a stage I STAMINA-001 study. The study is aimed at evaluating the safety and tolerability of ATG-037 as a mm88 casinootherapy as well as in combinatim88 casino with MSD’s anti-PD-1 therapy, pembrolizumab, for patients with locally advanced or metastatic solid tumors, to determine the appropriate dose for Phase II studies.

Under the terms of the agreement, the study will be cm88 casinoducted by Antengene, and MSD will provide pembrolizumab for the combinatim88 casino portim88 casinos of the trial.

m88 casino was engaged by Antengene to review and revise the transaction documents. The team was highly recognized for its efficient and prudent delivery of professional legal services.

This project was led by partnerand undertaken by partnerm88 sport betting.